Global Intussusception Market Growth, Share, Size, Trends and Forecast (2025 - 2031)
By Product;
Iron Dextran, Iron Sucrose, Ferric Carboxymaltose, and Others.By Treatment Type;
Surgical, Non-Surgical, and Medication.By Diagnostic Method;
Ultrasound, CT Scan, and X-Ray.By Application;
Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer, and Others.By Geography;
North America, Europe, Asia Pacific, Middle East & Africa, and Latin America - Report Timeline (2021 - 2031).Introduction
Global Intussusception Market (USD Million), 2021 - 2031
In the year 2024, the Global Intussusception Market was valued at USD 6,577.20 million. The size of this market is expected to increase to USD 8,890.88 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 4.4%.
Global Intussusception Market Growth, Share, Size, Trends and Forecast
*Market size in USD million
CAGR 4.4 %
Study Period | 2025 - 2031 |
---|---|
Base Year | 2024 |
CAGR (%) | 4.4 % |
Market Size (2024) | USD 6,577.20 Million |
Market Size (2031) | USD 8,890.88 Million |
Market Concentration | High |
Report Pages | 315 |
Major Players
- AbbVie Inc.
- AMAG Pharmaceuticals (Covis Pharma)
- Daiichi Sankyo Company, Ltd.
- Sanofi
- Vifor Pharma Management Ltd. (CSL)
- PHARMACOSMOS A/S
- Zydus Group
Market Concentration
Consolidated - Market dominated by 1 - 5 major players
Global Intussusception Market
Fragmented - Highly competitive market without dominant players
The global intussusception market is seeing remarkable expansion due to heightened awareness and significant advancements in diagnostic and treatment techniques for this urgent medical condition. Intussusception, where part of the intestine telescopes into another section, primarily affects young children. The increasing rate of diagnoses, coupled with the availability of effective treatments, has spurred growth in the market for medical interventions and therapeutic solutions.
Advancements in Early Detection and Treatment
With early detection critical for optimal outcomes, about 20% of intussusception cases in children require surgical intervention. However, non-invasive treatments such as ultrasound-guided reduction are now being widely adopted, driving a shift towards more effective, minimally invasive options. This advancement has resulted in a significant reduction in the need for surgery and improved patient recovery rates.
Technological Breakthroughs Shaping Treatment Options
Technological progress in minimally invasive procedures and non-surgical reduction techniques is transforming how intussusception is treated. These innovations have significantly improved treatment success rates, with over 75% of cases now treated successfully without the need for surgery. Additionally, enhanced imaging technologies and the integration of robotic assistance in surgery are making procedures faster and more accurate.
Rising Public Awareness and Enhanced Healthcare Systems
As public awareness of pediatric health issues grows, more parents and caregivers are seeking immediate medical attention, contributing to market expansion. The continuous improvement in healthcare infrastructure, along with better education for healthcare professionals on diagnosing and managing pediatric emergencies, is expected to drive a 5–8% compound annual growth rate (CAGR) in the market over the coming years.
Global Intussusception Market Recent Developments
-
In December 2019, Baxter expanded its product portfolio by acquiring the Seprafilm adhesion barrier and related assets from Sanofi, a key player in the market. This strategic acquisition enhanced Baxter's existing hemostat and sealant offerings, significantly boosting its competitive edge. By incorporating Seprafilm, Baxter strengthened its position in the intussusception treatment market, aligning its solutions with the growing demand for effective adhesion prevention in surgical settings. The acquisition represents a key move in Baxter's ongoing efforts to enhance patient outcomes and expand its market footprint.
-
In December 2017, BD strengthened its position in the global medical device technology sector by acquiring C.R. Bard. This strategic move combined their resources and significantly advanced BD's leadership in markets like adhesion barriers. Then, in October 2018, FzioMed introduced the Oxiplex/IU Intrauterine Adhesion Barrier gel, further expanding its presence in the intussusception treatment market. These developments highlight the increasing focus on innovation and collaboration within the industry to enhance treatment options and address growing market demand.
Segment Analysis
In this report, The Global Intussusception Market has been segmented by Product, Treatment Method, Diagnostic Method, Application, and Geography.
Global Intussusception Market, Segmentation by Product
The Global Intussusception Market has been segmented by Product into Iron Dextran, Iron Sucrose, Ferric Carboxymaltose, and Others.
Iron Dextran
Iron Dextran is one of the most commonly used intravenous iron supplements in the treatment of iron deficiency anemia associated with conditions like chronic kidney disease. It holds a significant share of the market, accounting for around 35%. The product’s high efficacy and long-term benefits make it a preferred choice among healthcare providers, especially for patients requiring long-term iron therapy.
Iron Sucrose
Iron Sucrose is a widely used intravenous iron product, particularly favored for its safety profile and quicker infusion time compared to other iron formulations. It accounts for approximately 30% of the global Intussusception market. Its use is rising steadily due to fewer side effects and better patient tolerance, making it a popular option for iron deficiency treatment in patients with chronic kidney diseases.
Ferric Carboxymaltose
Ferric Carboxymaltose has emerged as a prominent player in the iron supplementation market, contributing around 25% to the global market. It is preferred for its higher iron dose capacity and faster administration, providing efficient and rapid replenishment of iron stores in patients with iron deficiency anemia. This has led to an increasing adoption rate, particularly in clinical settings with patients suffering from more severe forms of anemia.
Others
The "Others" segment, which includes various alternative iron supplements like ferric pyrophosphate citrate and others, accounts for the remaining 10% of the market. While this segment is smaller, it continues to show steady growth as patients and healthcare providers seek different options that might offer improved tolerability or specific advantages in certain medical conditions.
The Global Intussusception Market, Segmentation by Treatment type
The Global Intussusception Market has been segmented by Treatment type into Surgical, Non-Surgical, and Medication.
Surgical
Surgical treatment is the most common approach for addressing intussusception, particularly in severe cases or when non-surgical methods are unsuccessful. It accounts for approximately 60% of the global treatment market. Surgery is often required to remove the affected portion of the intestine and prevent complications like bowel obstruction or necrosis. The high success rate and effectiveness of surgical intervention contribute to its significant share in the market.
Non-Surgical
Non-surgical treatments are frequently used for treating intussusception in less severe cases, especially in children. This approach, which includes enema reduction techniques, accounts for about 25% of the market. Non-surgical methods are preferred due to their less invasive nature, quicker recovery times, and lower risk of complications, making them an attractive option for both patients and healthcare providers.
Medication
Medications, such as antibiotics and corticosteroids, are used to manage intussusception in certain cases, especially when there is a risk of infection or inflammation. This treatment modality represents approximately 15% of the market. Although not a primary treatment, medication is essential for supporting recovery, particularly in cases where inflammation and infection are present in conjunction with the condition.
The Global Intussusception Market, Segmentation by Diagnostic Method
The Global Intussusception Market has been segmented by Diagnostic method into Ultrasound, CT Scan, and X-Ray.
Ultrasound
Ultrasound is one of the most commonly used diagnostic methods for intussusception due to its non-invasive nature and quick results. It holds a significant share of approximately 50% of the global diagnostic market. Ultrasound allows real-time imaging, making it ideal for detecting bowel obstructions and intussusception, particularly in pediatric patients, where radiation exposure needs to be minimized.
CT Scan
CT Scan is a highly accurate and detailed diagnostic method, preferred for its ability to provide comprehensive imaging of the abdomen, especially in complex cases of intussusception. It accounts for around 30% of the market. CT scans are commonly used when ultrasound results are inconclusive or when more detailed images are needed to assess the severity of the condition and the extent of bowel involvement.
X-Ray
X-rays are used as a supplementary diagnostic tool in intussusception cases, often to assess the presence of bowel obstruction or other related complications. Although they account for about 20% of the market, X-rays are less commonly used as the primary diagnostic method for intussusception due to their limited ability to clearly visualize soft tissues compared to ultrasound or CT scans. However, they are still valuable for detecting general signs of bowel obstruction.
Global Intussusception Market, Segmentation by Application
The Global Intussusception Market has been segmented by Application into Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer, and Others.
Chronic Kidney Disease
Chronic Kidney Disease (CKD) is one of the leading contributors to the global intussusception market, accounting for approximately 40% of the total market share. CKD patients are more susceptible to gastrointestinal complications, including intussusception, due to issues such as fluid imbalances and impaired bowel motility. As the global prevalence of CKD continues to rise, the demand for effective treatments targeting intussusception in these patients is expected to increase significantly.
Inflammatory Bowel Disease
Inflammatory Bowel Disease (IBD), which includes conditions like Crohn’s disease and ulcerative colitis, holds a significant share of the intussusception market at around 35%. Patients with IBD are more likely to experience bowel obstructions and other gastrointestinal disorders, making them more prone to developing intussusception. The increasing global prevalence of IBD further propels the need for treatments aimed at managing intussusception in these individuals.
Cancer
Cancer, particularly gastrointestinal cancers such as colorectal cancer, represents about 20% of the global intussusception market. Intussusception can occur in cancer patients when tumors in the abdominal region cause bowel obstruction. With the rising global incidence of cancer, especially colorectal and other gastrointestinal cancers, this market segment is poised for continued growth, driven by the need for effective treatment options.
Others
The "Others" segment, which includes various conditions such as infections, trauma, and congenital disorders, contributes approximately 5% to the intussusception market. While this segment is smaller in comparison, it is still significant as it encompasses a broad range of factors that can lead to intussusception. The diversity of conditions within this segment ensures its continued, albeit smaller, contribution to the overall market.
Global Intussusception Market, Segmentation by Geography
In this report, the Global Intussusception Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.
Global Intussusception Market Share (%), by Geographical Region, 2024
North America
North America leads the global intussusception market, contributing approximately 40% of the total market share. This dominance can be attributed to the region's advanced healthcare infrastructure, high levels of awareness, and a substantial population affected by conditions that increase the risk of intussusception, such as chronic kidney disease and inflammatory bowel disease. Additionally, ongoing research initiatives and cutting-edge medical treatments continue to bolster the region’s growth in the market.
Europe
Europe holds around 30% of the global intussusception market. The region benefits from robust healthcare systems, top-tier medical facilities, and an increasing prevalence of gastrointestinal conditions such as Crohn’s disease and colorectal cancer. These factors, combined with the region's commitment to advancing healthcare and medical technologies, are expected to fuel continued market growth in Europe.
Asia Pacific
The Asia Pacific region is projected to experience rapid growth in the intussusception market, with an expected market share of approximately 20%. The rise in gastrointestinal disorders such as cancer and inflammatory bowel disease, along with significant economic development and improved healthcare access in countries like China and India, are key factors driving this growth. The expanding healthcare infrastructure and rising awareness in the region will continue to support the market's expansion.
Middle East and Africa
The Middle East and Africa (MEA) region holds a smaller portion of the global intussusception market, contributing around 5%. While the market share is lower, the region is witnessing improvements in healthcare investments, access to treatments, and public awareness of gastrointestinal diseases. These factors are expected to drive gradual growth in the intussusception market within the MEA region, even as it lags behind other global regions.
Latin America
Latin America accounts for about 5% of the global intussusception market. Although the region faces challenges such as economic disparities and varying healthcare access, improvements in healthcare systems and an increase in chronic disease prevalence are expected to stimulate market growth. As healthcare continues to improve, the demand for effective intussusception treatments in Latin America is projected to rise, contributing to the region’s growth in the market.
Market Trends
This report provides an in depth analysis of various factors that impact the dynamics of Global Intussusception Market. These factors include; Market Drivers, Restraints and Opportunities.
Drivers:
- Pediatric Population Increase
- Advanced Diagnostic Technologies
-
Surgical Advancements - One key area of surgical advancement lies in the development and refinement of minimally invasive surgical techniques for the treatment of intussusception. Laparoscopic and robotic-assisted procedures have emerged as viable alternatives to traditional open surgery, offering several advantages such as smaller incisions, reduced postoperative pain, shorter hospital stays, and faster recovery times for patients. These minimally invasive approaches allow for precise visualization and manipulation of the affected bowel segments, facilitating gentle reduction of the intussusception and minimizing tissue trauma, thereby reducing the risk of postoperative complications and enhancing patient satisfaction.
Advancements in surgical imaging technologies have contributed to improved intraoperative visualization and localization of the intussusception, enabling surgeons to accurately identify the affected bowel segments and plan the surgical approach accordingly. Techniques such as intraoperative ultrasound and fluoroscopy-guided reduction have enhanced the precision and success rates of surgical interventions, particularly in complex or recurrent cases of intussusception.
Restraints:
- Treatment Complexity
- Limited Awareness
-
Healthcare Accessibility - One of the primary barriers to healthcare accessibility in the context of intussusception is the uneven distribution of healthcare infrastructure and services, with rural and remote areas often facing shortages of healthcare facilities, medical professionals, and diagnostic equipment. As a result, individuals residing in these areas may experience delays in seeking medical attention for symptoms suggestive of intussusception, leading to diagnostic delays and potentially worse clinical outcomes.
Socioeconomic factors such as poverty, lack of health insurance coverage, and financial constraints can impede individuals' ability to access healthcare services for the diagnosis and treatment of intussusception. High out-of-pocket healthcare expenses may deter patients from seeking timely medical care, exacerbating disparities in healthcare access and contributing to preventable morbidity and mortality associated with intussusception-related complications.
Cultural and linguistic barriers can further hinder healthcare accessibility for certain population groups, including minority communities and non-native speakers of the predominant language. Limited health literacy and communication difficulties may compromise patients' understanding of intussusception symptoms, treatment options, and the importance of seeking timely medical attention, leading to suboptimal healthcare utilization and outcomes.
Opportunities:
- Early Intervention Strategies
- Minimally Invasive Procedures
-
Emerging Markets Expansion - One key factor driving the expansion of the Global Intussusception Market in emerging markets is the growing burden of gastrointestinal diseases, including intussusception, due to changing demographics, urbanization, and shifts in lifestyle and dietary patterns. As these regions undergo demographic transitions, with larger populations living in urban areas and adopting Westernized diets, the incidence and prevalence of gastrointestinal disorders are expected to rise, creating a greater demand for diagnostic and therapeutic interventions for conditions such as intussusception.
Improving healthcare infrastructure and access to healthcare services in emerging markets are facilitating earlier diagnosis and intervention for gastrointestinal conditions, including intussusception. Enhanced availability of diagnostic imaging modalities, such as ultrasound and computed tomography (CT) scans, enables healthcare providers to accurately diagnose intussusception and assess its severity, leading to timely treatment and improved patient outcomes.
Rising healthcare expenditure and increasing investment in healthcare infrastructure in emerging markets are driving the adoption of advanced therapeutic interventions for intussusception, including minimally invasive surgical techniques and novel pharmacological treatments. These advancements in treatment modalities are improving patient outcomes, reducing hospital stays, and enhancing the overall quality of care for individuals affected by intussusception in these regions.
Competitive Landscape Analysis
Key players in Global Intussusception Market include:
- AbbVie Inc.
- AMAG Pharmaceuticals (Covis Pharma)
- Daiichi Sankyo Company, Ltd.
- Sanofi
- Vifor Pharma Management Ltd. (CSL)
- PHARMACOSMOS A/S
- Zydus Group
In this report, the profile of each market player provides following information:
- Company Overview and Product Portfolio
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
- Introduction
- Research Objectives and Assumptions
- Research Methodology
- Abbreviations
- Market Definition & Study Scope
- Executive Summary
- Market Snapshot, By Product
- Market Snapshot, By Treatment Type
- Market Snapshot, By Diagnostic Method
- Market Snapshot, By Application
- Market Snapshot, By Region
- Global Intussusception Market Dynamics
- Drivers, Restraints and Opportunities
- Drivers
-
Pediatric Population Increase
-
Advanced Diagnostic Technologies
-
Surgical Advancements
-
- Restraints
-
Treatment Complexity
-
Limited Awareness
-
Healthcare Accessibility
-
- Opportunities
-
Early Intervention Strategies
-
Minimally Invasive Procedures
-
Emerging Markets Expansion
-
- Drivers
- PEST Analysis
- Political Analysis
- Economic Analysis
- Social Analysis
- Technological Analysis
- Porter's Analysis
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Threat of New Entrants
- Competitive Rivalry
- Drivers, Restraints and Opportunities
- Market Segmentation
- Global Intussusception Market, By Product, 2021 - 2031 (USD Million)
-
Iron Dextran
-
Iron Sucrose
-
Ferric Carboxymaltose
-
Others
-
-
Global Intussusception Market, By Treatment Type, 2021 - 2031 (USD Million)
-
Surgical
-
Non-Surgical
-
Medication
-
-
Global Intussusception Market, By Diagnostic Method, 2021 - 2031 (USD Million)
-
Ultrasound
-
CT Scan
-
X-Ray
-
- Global Intussusception Market, By Application, 2021 - 2031 (USD Million)
-
Chronic Kidney Disease
-
Inflammatory Bowel Disease
-
Cancer
-
Others
-
- Global Intussusception Market, By Geography, 2021 - 2031 (USD Million)
- North America
- United States
- Canada
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Nordic
- Benelux
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia & New Zealand
- South Korea
- ASEAN (Association of South East Asian Countries)
- Rest of Asia Pacific
- Middle East & Africa
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- North America
- Global Intussusception Market, By Product, 2021 - 2031 (USD Million)
- Competitive Landscape
- Company Profiles
- AbbVie Inc.
- AMAG Pharmaceuticals (Covis Pharma)
- Daiichi Sankyo Company, Ltd.
- Sanofi
- Vifor Pharma Management Ltd. (CSL)
- PHARMACOSMOS A/S
- Zydus Group
- Company Profiles
- Analyst Views
- Future Outlook of the Market